These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
524 related items for PubMed ID: 1343113
1. Acute and chronic effects of dexfenfluramine on glucose and insulin response to intravenous glucose in diabetic and non-diabetic obese subjects. Glaser B, Raveh Y, Norynberg C, Berry E, Lavielle R, Nathan C, Cerasi E. Diabetes Res; 1992; 19(4):165-76. PubMed ID: 1343113 [Abstract] [Full Text] [Related]
3. Glucose disposal in obese non-diabetic and diabetic type II patients. A study by indirect calorimetry and euglycemic insulin clamp. Golay A, Defronzo RA, Thorin D, Jequier E, Felber JP. Diabete Metab; 1988; 14(4):443-51. PubMed ID: 3066652 [Abstract] [Full Text] [Related]
6. Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Mather KJ, Paradisi G, Leaming R, Hook G, Steinberg HO, Fineberg N, Hanley R, Baron AD. Diabetes Metab Res Rev; 2002; 18(2):118-26. PubMed ID: 11994903 [Abstract] [Full Text] [Related]
9. Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity. Yoshinaga H, Kosaka K. Diabetes Res Clin Pract; 1999 May; 44(2):129-36. PubMed ID: 10414932 [Abstract] [Full Text] [Related]
10. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441 [Abstract] [Full Text] [Related]
12. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ. J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877 [Abstract] [Full Text] [Related]
14. In obese individuals dexfenfluramine corrects molecular derangements reflecting insulin resistance. Piccinini M, Rabbone I, Novi RF, Alberto G, Mostert M, Musso A, Vai S, Gamba S, Rinaudo MT. Int J Obes Relat Metab Disord; 2000 Jun; 24(6):735-41. PubMed ID: 10878680 [Abstract] [Full Text] [Related]
18. Insulin secretion and insulin action in Taiwanese with type 2 diabetes. Shen DC, Kuo SW, Shian LR, Fuh MT, Wu DA, Chen YD, Reaven GM. Diabetes Res Clin Pract; 1988 Apr 06; 4(4):289-93. PubMed ID: 2897274 [Abstract] [Full Text] [Related]
19. Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus. Greco AV, Mingrone G, Capristo E, De Gaetano A, Ghirlanda G, Castagneto M. Metabolism; 1995 Feb 06; 44(2 Suppl 2):57-61. PubMed ID: 7869940 [Abstract] [Full Text] [Related]
20. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. Chow CC, Ko GT, Tsang LW, Yeung VT, Chan JC, Cockram CS. Diabetes Care; 1997 Jul 06; 20(7):1122-7. PubMed ID: 9203448 [Abstract] [Full Text] [Related] Page: [Next] [New Search]